Management of negative symptoms of schizophrenia

Current Psychiatry Reports

Volumn 3, Issue 5, 2001, Pages 413-417

  Javitt, Daniel C ^a  

^a NATHAN S KLINE INSTITUTE FOR PSYCHIATRIC RESEARCH   (United States)

Author keywords

Clozapine; Negative Symptom; Olanzapine; Risperidone; Schizophrenia

Indexed keywords

NEUROLEPTIC AGENT;

AFFECT; CLASSIFICATION; HUMAN; REVIEW; SCHIZOPHRENIA;

AFFECT; ANTIPSYCHOTIC AGENTS; HUMANS; SCHIZOPHRENIA;

EID: 0001278077     PISSN: 15233812     EISSN: 15351645     Source Type: Journal    
DOI: 10.1007/s11920-996-0036-9     Document Type: Article

References (38)

1. Mass R, Schoemig T, Hitschfeld K, et al.: Psychopathological syndromes of schizophrenia: evaluation of the dimensional structure of the positive and negative syndrome scale. Schizophr Bull 2000, 26:167–77.
2. Lancon C, Auquier P, Nayt G, Reine G: Stability of the fivefactor structure of the Positive and Negative Syndrome Scale (PANSS). Schizophr Res 2000, 42:231–239. DOI: 10.1016/S0920-9964(99)00129-2
3. Gilbert EA, Liberman RP, Ventura J, et al.: Concurrent validity of negative symptom assessments in treatment refractory schizophrenia: relationship between interview-based ratings and inpatient ward observations. J Psychiatr Res 2000, 34:443–447. DOI: 10.1016/S0022-3956(00)00041-8
4. Kirkpatrick B, Buchanan RW, Ross DE, Carpenter WT, Jr: A separate disease within the syndrome of schizophrenia. Arch Gen Psychiatry 2001, 58:165–171. Reviews the concept of the deficit syndrome and its relationship to persistent negative and cognitive symptoms of schizophrenia. DOI: 10.1001/archpsyc.58.2.165
5. Bryson G, Whelahan HA, Bell M: Memory and executive function impairments in deficit syndrome schizophrenia. Psychiatry Res 2001, 102:29–37. DOI: 10.1016/S0165-1781(01)00245-1
6. Tandon R, DeQuardo JR, Taylor SF, et al.: Phasic and enduring negative symptoms in schizophrenia: biological markers and relationship to outcome. Schizophr Res 2000, 45:191–201. DOI: 10.1016/S0920-9964(99)00163-2
7. Peralta V, Cuesta MJ, Martinez-Larrea A, Serrano JF: Differentiating primary from secondary negative symptoms in schizophrenia: a study of neurolepticnaive patients before and after treatment. Am J Psychiatry 2000, 157:1461–1466. DOI: 10.1176/appi.ajp.157.9.1461
8. Bilder RM, Goldman RS, Robinson D, et al.: Neuropsychology of first-episode schizophrenia: initial characterization and clinical correlates. Am J Psychiatry 2000, 157:549–559. Comprehensive presentation of neuropsychological deficits in first-episode schizophrenia patients and their relationship to negative and cognitive symptoms. DOI: 10.1176/appi.ajp.157.4.549
9. Nieuwenstein MR, Aleman A, de Haan EH: Relationship between symptom dimensions and neurocognitive functioning in schizophrenia: a meta-analysis of WCST and CPT studies. J Psychiatr Res 2001, 35:119–125. DOI: 10.1016/S0022-3956(01)00014-0
10. O’Leary DS, Flaum M, Kesler ML, et al.: Cognitive correlates of the negative, disorganized, and psychotic symptom dimensions of schizophrenia. J Neuropsychiatry Clin Neurosci 2000, 12:4–15.
11. McGurk SR, Moriarty PJ, Harvey PD, et al.: Relationship of cognitive functioning, adaptive life skills, and negative symptom severity in poor-outcome geriatric schizophrenia patients. J Neuropsychiatry Clin Neurosci 2000, 12:257–264.
12. McGurk SR, Moriarty PJ, Harvey PD, et al.: The longitudinal relationship of clinical symptoms, cognitive functioning, and adaptive life in geriatric schizophrenia. Schizophr Res 2000, 42:47–55. DOI: 10.1016/S0920-9964(99)00097-3
13. Mathalon DH, Ford JM, Pfefferbaum A: Trait and state aspects of P300 amplitude reduction in schizophrenia: a retrospective longitudinal study. Biol Psychiatry 2000, 47:434–49. DOI: 10.1016/S0006-3223(99)00277-2
14. Kiehl KA, Liddle PF: An event-related functional magnetic resonance imaging study of an auditory oddball task in schizophrenia. Schizophr Res 2001, 48:159–71. DOI: 10.1016/S0920-9964(00)00117-1
15. Javitt DC, Shelley A, Ritter W: Associated deficits in mismatch negativity generation and tone matching in schizophrenia. Clin Neurophysiol 2000, 111:1733–1737. DOI: 10.1016/S1388-2457(00)00377-1
16. Javitt DC: Intracortical mechanisms of mismatch negativity dysfunction in schizophrenia. Audiol Neurootol 2000, 5:207–215. DOI: 10.1159/000013882
17. Kapur S, Seeman P: Does fast dissociation from the dopamine D(2) receptor explain the action of atypical antipsychotics? A new hypothesis. Am J Psychiatry 2001, 158:360–369. DOI: 10.1176/appi.ajp.158.3.360
18. Chakos M, Lieberman J, Hoffman E, et al.: Effectiveness of second-generation antipsychotics in patients with treatmentresistant schizophrenia: a review and meta-analysis of randomized trials. Am J Psychiatry 2001, 158:518–526. Comprehensive review and meta-analysis of studies investigating potential effects of atypical antipsychotics on negative and cognitive symptoms. DOI: 10.1176/appi.ajp.158.4.518
19. Emsley RA, Raniwalla J, Jones AM: A comparison of the effects of quetiapine and haloperidol in schizophrenic pateints with a history of and a demonstrated, partial response to conventional antipsychotic treatment. Int Clin Psychopharmacol 2000, 15:121–131.
20. Conley RR, Mahmoud R: A randomized double-blind study of risperidone and olanzapine in the treatment of schizophrenia or schizoaffective disorder. Am J Psychiatry 2001, 158:765–774. DOI: 10.1176/appi.ajp.158.5.765
21. Sharif ZA, Raza A, Ratakonda SS: Comparative efficacy of risperidone and clozapine in the treatment of patients with refractory schizophrenia or schizoaffective disorder: a retrospective analysis. J Clin Psychiatry 2000, 61:498–504. DOI: 10.4088/JCP.v61n0707
22. Cuesta MJ, Peralta V, Zarzuela A: Effects of olanzapine and other antipsychotics on cognitive function in chronic schizophrenia: a longitudinal study. Schizophr Res 2001, 48:17–28. DOI: 10.1016/S0920-9964(00)00112-2
23. Javitt DC, Shelley AM, Silipo G, Lieberman JA: Deficits in auditory and visual context-dependent processing in schizophrenia: defining the pattern. Arch Gen Psychiatry 2000, 57:1131–1137. Study demonstrating role of NMDA dysfunction in etiology of specific neurophysiologic and neuropsychologic deficits associated with schizophrenia (also [24]). DOI: 10.1001/archpsyc.57.12.1131
24. Umbricht D, Schmid L, Koller R, et al.: Ketamineinduced deficits in auditory and visual contextdependent processing in healthy volunteers: implications for models of cognitive deficits in schizophrenia. Arch Gen Psychiatry 2000, 57:1139–1147. Study demonstrating role of NMDA dysfunction in etiology of specific neurophysiologic and neuropsychologic deficits associated with schizophrenia (also [23]). DOI: 10.1001/archpsyc.57.12.1139
25. Krystal JH, Bennett A, Abi-Saab D, et al.: Dissociation of ketamine effects on rule acquisition and rule implementation: possible relevance to NMDA receptor contributions to executive cognitive functions. Biol Psychiatry 2000, 47:137–143. DOI: 10.1016/S0006-3223(99)00097-9
26. Linn G, Javitt DC: Phencyclidine (PCP) induced deficits of prepulse inhibition in monkeys. Neuroreport 2000, 12:117–120. First demonstration of PCP-induced impairments in prepulse inhibition in monkeys, indicating role for NMDA receptors in cognitive dysfunction in schizophrenia. DOI: 10.1097/00001756-200101220-00031
27. Javitt DC, Lindsley RW: Effects of phencyclidine on prepulse inhibition of acoustic startle response in the Macaque. Psychophysiol 2001, In press.
28. Noda Y, Kamei H, Mamiya T, et al.: Repeated phencyclidine treatment induces negative symptom-like behavior in forced swimming test in mice: imbalance of prefrontal serotonergic and dopaminergic functions. Neuropsychopharmacology 2000, 23:375–387. DOI: 10.1016/S0893-133X(00)00138-X
29. Linn GS, O’Keeffe RT, Schroeder CE, et al.: Behavioral effects of chronic phencyclidine in monkeys. Neuroreport 1999, 10:2789–2793. DOI: 10.1097/00001756-199909090-00017
30. Balla A, Koneru R, Smiley J, et al.: Continuous phencyclidine treatment induces schizophrenia-like hyperreactivity of striatal dopamine release. Neuropsychopharmacology 2001, In press.
31. Javitt DC, Silipo G, Cienfuegos A, et al.: Adjunctive high-dose glycine in the treatment of schizophrenia. Int J Neuropsychopharmacology 2001, In press. Clinical study showing effectiveness of glycine treatment in combination with newer atypical antipsychotics and clozapine.
32. Heresco-Levy U, Ermilov M, Silipo G, et al.: Placebo-controlled trial of D-cycloserine added to conventional neuroleptics, olanzapine and risperidone in schizophrenia. Am J Psychiatry 2001, In press. Clinical study showing effectiveness of D-cycloserine treatment in combination with newer atypical antipsychotics and clozapine.
33. Evins AE, Fitzgerald SM, Wine L, et al.: Placebo-controlled trial of glycine added to clozapine in schizophrenia. Am J Psychiatry 2000, 157:826–828. DOI: 10.1176/appi.ajp.157.5.826
34. Bantick RA, Deakin JF, Grasby PM: The 5-HT1A receptor in schizophrenia: a promising target for novel atypical neuroleptics? J Psychopharmacol 2001, 15:37–46. DOI: 10.1177/026988110101500108
35. Wedzony K, Mackowiak M, Czyrak A, et al.: Single doses of MK-801, a non-competitive antagonist of NMDA receptors, increase the number of 5-HT1A serotonin receptors in the rat brain. Brain Res 1997, 756:84–91. DOI: 10.1016/S0006-8993(97)00159-5
36. Berk M, Ichim C, Brook S: Efficacy of mirtazapine add on therapy to haloperidol in the treatment of the negative symptoms of schizophrenia: a double-blind randomized placebo-controlled study. Int Clin Psychopharmacol 2001, 16:87–92. DOI: 10.1097/00004850-200103000-00003
37. Sumiyoshi T, Matsui M, Yamashita I, et al.: The effect of tandospirone, a serotonin(1A) agonist, on memory function in schizophrenia. Biol Psychiatry 2001, 49:861–868. DOI: 10.1016/S0006-3223(00)01025-8
38. Millan MJ: Improving the treatment of schizophrenia: focus on serotonin (5-HT1A) receptors. J Pharmacol Exp Ther 2000, 295:853–861.